Skip to content

US · ARGX · BIOTECHNOLOGY

argenx SE (ARGX) intrinsic value and stock valuation

$925.70as of 2026-11-21 · Mkt cap 53.98B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

argenx SE DCF and intrinsic value

InvestorsCraft values ARGX with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ARGX’s statements →

argenx SE Graham Number

Graham Number: $238.04d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Amsterdam, NH 1101EB argen-x.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$4.15B+151.5% 5y CAGRd
20112025
Net income
$1.29B
20112025
Free cash flow
$844.3M
20112025
Total equity
$7.32B+34.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$4.15B$2.19B$1.23B$410.8M$1.08B
Operating income$1.05B-$-21.65M-$-425.05M-$-720.34M-$-348.75M
Net income$1.29B$833M-$-295.05M-$-709.59M-$-408.26M
EPSd$19.6M$12.8M-$-5.16M-$-13.05M-$-7.99M
Operating cash flow$850.5M-$-82.75M-$-420.33M-$-862.81M-$-606.81M
Capital expenditure-$-6.18M-$-68.3M-$-43.81M-$-103.82M-$-121.43M
Free cash flow$844.3M-$-151.05M-$-464.14M-$-966.63M-$-728.25M
Total assets$8.68B$6.2B$4.54B$3.13B$2.85B
Total debt$83.5M$39.1M$20M$12.4M$11.5M
Net debt-$-3.41B-$-1.46B-$-2.03B-$-788.31M-$-1.32B
Total equity$7.32B$5.5B$4.1B$2.81B$2.53B
Cash and short-term investments$4.44B$3.38B$3.18B$2.19B$2.34B
Income statement
20252024202320222021
Revenue$4.15B$2.19B$1.23B$410.8M$1.08B
Cost of revenue$450.7M$227.3M$117.8M$29.4M$580.5M
Gross profit$3.7B$1.96B$1.11B$381.3M$497.3M
Research and development expenses$1.36B$983.4M$859.5M$663.4M$580.5M
Selling, general and administrative expenses$1.36B$1.06B$709.5M$469.9M$305.5M
Other expenses-$-75.91M-$-54.16M-$-35.5M-$-31.63M-$-40.02M
Operating expenses$2.65B$1.98B$1.53B$1.1B$846M
Cost and expenses$3.1B$2.21B$1.65B$1.13B$1.43B
Interest income$163.1M$138.5M$93M$24.7M$3.48M
Interest expense$4.08M$2.22M$900K$2.19M$1.1M
Depreciation and amortization$28.1M$17.5M$111.5M$104.3M$5.87M
Ebitda$1.31B$105.2M-$-192.28M-$-622.78M-$-392.78M
Operating income$1.05B-$-21.65M-$-425.05M-$-720.34M-$-348.75M
Total other income/expenses, net$224M$106.8M$120.6M-$-8.97M-$-51M
Income before tax$1.28B$85.2M-$-304.5M-$-729.31M-$-399.74M
Income tax expense-$-13.43M-$-747.86M-$-9.44M-$-19.72M$8.52M
Net income$1.29B$833M-$-295.05M-$-709.59M-$-408.26M
Weighted average shares outstanding$61.3M$59.9M$57.2M$54.4M$51.1M
Weighted average diluted shares outstanding$66M$65.2M$57.2M$54.4M$51.1M
Balance sheet
20252024202320222021
Cash and short-term investments$4.44B$3.38B$3.18B$2.19B$2.34B
Net receivables$1.66B$909.1M$499.3M$277.3M$38.2M
Inventory$473.5M$407.2M$310.6M$228.4M$109.1M
Total current assets$6.9B$4.88B$4.12B$2.77B$2.54B
Property, plant and equipment, net$48.3M$43.5M$22.7M$16.2M$15.8M
Goodwill and intangible assets$272.1M$181.4M$125.2M$174.9M$171.7M
Long-term investments$89.6M$49.7M$47.2M$40.5M$53.2M
Total non-current assets$1.78B$1.32B$418.7M$360.1M$307.3M
Total assets$8.68B$6.2B$4.54B$3.13B$2.85B
Accounts payable$1.27B$342.2M$245.6M$188.7M$208.9M
Short-term debt$10.8M$6.53M$4.65M$3.42M$3.51M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.32B$669.9M$423M$302.3M$301.2M
Long-term debt$72.7M$32.5M$15.4M$9.01M$7.96M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$39.4M$34.3M$22M$18.3M$14.8M
Capital lease obligations$36.3M$32.5M$15.4M$9.01M$7.96M
Total liabilities$1.36B$704.2M$445M$320.6M$316.1M
Common stock$7.35M$6.98M$6.39M$6.64M$6.23M
Retained earnings-$-279.77M-$-1.57B-$-2.4B-$-2.11B-$-1.4B
Accumulated other comprehensive income (loss)$73.6M$66.7M$72.1M$71.7M$465.4M
Total equity$7.32B$5.5B$4.1B$2.81B$2.53B
Total investments$1.04B$1.93B$1.18B$1.43B$1.06B
Total debt$83.5M$39.1M$20M$12.4M$11.5M
Net debt-$-3.41B-$-1.46B-$-2.03B-$-788.31M-$-1.32B
Cash flow statement
20252024202320222021
Net income$1.05B$833M-$-425.05M-$-720.34M-$-348.75M
Depreciation and amortization$28.1M$17.5M$111.3M$104.3M$5.87M
Stock-based compensation$248.1M$235.2M$233M$157M$179.4M
Change in working capital-$-423.94M-$-324.6M-$-308.89M-$-375.93M-$-340.95M
Accounts receivable-$-804.81M-$-422.36M-$-185.69M-$-222.26M-$-31.63M
Inventory-$-99.26M-$-95.83M-$-83.03M-$-119.28M-$-83.88M
Accounts payable$614.2M$245.9M$0.00$0.00$0.00
Net cash provided by operating activities$850.5M-$-82.75M-$-420.33M-$-862.81M-$-606.81M
Investments in property, plant and equipment-$-112.03M-$-1.8M-$-810K-$-840K-$-3.62M
Acquisitions, net$0.00-$-7M-$-13M-$-2M$0.00
Net cash used for investing activities$823.9M-$-717.59M$308.2M-$-461.18M-$-347.07M
Common stock issued$279.2M$308.7M$1.2B$761M$1.12B
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$233.7M$279.8M$1.34B$843.8M$1.12B
Net change in cash$1.99B-$-548.91M$1.25B-$-533.94M$117.9M
Cash at end of period$3.49B$1.5B$2.05B$800.7M$1.33B
Operating cash flow$850.5M-$-82.75M-$-420.33M-$-862.81M-$-606.81M
Capital expenditure-$-6.18M-$-68.3M-$-43.81M-$-103.82M-$-121.43M
Free cash flow$844.3M-$-151.05M-$-464.14M-$-966.63M-$-728.25M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About argenx SE

        argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.

        CEO
        Karen Massey
        Employees
        1.86K
        Beta
        -0.02

        Explore

        Frequently asked questions

        What is the intrinsic value of argenx SE (ARGX)?

        argenx SE (ARGX) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ARGX undervalued?

        ARGX trades at a price of $925.70 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.